A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) (clinicaltrials.gov) - Oct 14, 2026 - P1/2 | N=55 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting
Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|